YZYBIO-B
- Country
- 🇨🇳China
- Ownership
- Public, Subsidiary
- Established
- 2010-07-08
- Employees
- 114
- Market Cap
- -
- Website
- http://yzybio.com
- Introduction
Wuhan Youzhiyou Biopharmaceutical Co., Ltd. is a biotechnology company dedicated to developing bispecific antibody (BsAb) -based therapies for the treatment of cancer-related complications, cancer, and senile ophthalmology to address medical needs in the fields of oncology and geriatric ophthalmology. The company's mission is to develop innovative medicines and protect human health.
Since its establishment in 2010, Tomochiyo Biotech has continued to innovate independently, lay out and deepen the field of bispecific antibodies, and has developed 4 innovative platforms, including the self-developed YBODY platform, the Check-body platform, the Nano-YbodyTM platform, and the UVAX platform developed in cooperation with the Wuhan Institute of Virology. The company has designed and developed seven clinical-stage drug candidate pipelines.
Clinical Trials
8
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody
- Conditions
- Malignant Ascites
- Interventions
- Procedure: paracentesis
- First Posted Date
- 2024-05-29
- Last Posted Date
- 2025-07-20
- Lead Sponsor
- Wuhan YZY Biopharma Co., Ltd.
- Target Recruit Count
- 312
- Registration Number
- NCT06432296
- Locations
- 🇨🇳
The First Medical Center of Chinese PLA General Hospital, Beijing, Beijing, China
🇨🇳Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
Treat Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer With M701 Bispecific Antibody
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2025-07-20
- Lead Sponsor
- Wuhan YZY Biopharma Co., Ltd.
- Target Recruit Count
- 115
- Registration Number
- NCT06266091
- Locations
- 🇨🇳
The First Medical Center of Chinese PLA General Hospital, Beijing, Beijing, China
A Trial of Y101D in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Advanced Pancreatic Cancer
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2025-07-20
- Lead Sponsor
- Wuhan YZY Biopharma Co., Ltd.
- Target Recruit Count
- 71
- Registration Number
- NCT06266143
- Locations
- 🇨🇳
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC
- Conditions
- Malignant Pleural EffusionsNSCLC Stage IV
- Interventions
- First Posted Date
- 2022-09-16
- Last Posted Date
- 2025-07-20
- Lead Sponsor
- Wuhan YZY Biopharma Co., Ltd.
- Target Recruit Count
- 96
- Registration Number
- NCT05543330
- Locations
- 🇨🇳
Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, China
A Trial of Y101D, a PD-L1/TGF-β Bispecific Antibody, in Patients With Metastatic or Locally Advanced Solid Tumors
- Conditions
- Metastatic or Locally Advanced Solid Tumors
- Interventions
- Drug: Cohort 1 of Y101DDrug: Cohort 2 of Y101DDrug: Cohort 3 of Y101DDrug: Cohort 4 of Y101DDrug: Cohort 5 of Y101D
- First Posted Date
- 2021-08-31
- Last Posted Date
- 2025-07-20
- Lead Sponsor
- Wuhan YZY Biopharma Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT05028556
- Locations
- 🇨🇳
Cancer Prevention Center, Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
- Prev
- 1
- 2
- Next